Compare JAKK & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JAKK | MOLN |
|---|---|---|
| Founded | 1995 | 2004 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 189.1M | 157.8M |
| IPO Year | 1996 | 2021 |
| Metric | JAKK | MOLN |
|---|---|---|
| Price | $16.56 | $3.96 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 1 |
| Target Price | ★ $36.67 | $3.75 |
| AVG Volume (30 Days) | ★ 92.0K | 3.4K |
| Earning Date | 10-30-2025 | 10-30-2025 |
| Dividend Yield | ★ 6.06% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.53 | N/A |
| Revenue | ★ $574,298,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.54 | $1,000.00 |
| P/E Ratio | $31.14 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $14.87 | $3.36 |
| 52 Week High | $35.79 | $5.91 |
| Indicator | JAKK | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 48.58 | 49.42 |
| Support Level | $16.24 | $3.92 |
| Resistance Level | $16.93 | $4.35 |
| Average True Range (ATR) | 0.51 | 0.18 |
| MACD | 0.08 | -0.03 |
| Stochastic Oscillator | 72.57 | 36.96 |
Jakks Pacific Inc is a multi-product line, multi-brand toy company that designs, produces, markets, sells and distributes toys and related kid-targeted consumer products, inclusive of kids indoor and outdoor furniture, costumes and various product lines in the sporting goods and home furnishings space. Its products offering include Traditional toys and electronics such as Action figures, Toy vehicles, Dolls and accessories, Ride-on toys, Toys for pets, and others. The company's products have been divided into two segments: (i) Toys/Consumer Products and (ii) Costumes.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.